

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the present application.

IN THE CLAIMS:

Claims 1 - 6. (Canceled).

Claim 7. (Currently Amended) A pharmaceutical composition that comprises as an active ingredient an isolated ~~the~~ protein ~~of claim 6~~ that is encoded by a DNA of any one of the following (a) to (d):

(a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO:1,

(b) a DNA comprising the nucleotide sequence of SEQ ID NO:2,

(c) a foreign DNA carried in *E. coli* JM109 (3D9) (deposit number FERM BP-6929), and

(d) a DNA which hybridizes with a DNA of any one of (a) to (c) under stringent hybridization conditions wherein said DNA encodes a tumor antigen protein which gives rise to tumor antigen peptide(s) that bind(s) to an HLA antigen and are recognized by cytotoxic T lymphocytes.

8. (Currently Amended) A pharmaceutical composition for treating ~~or preventing~~ tumors, which comprises as an active ingredient an isolated the protein of claim 6 that is encoded by a DNA of any one of the following (a) to (d):

(a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO:1,

(b) a DNA comprising the nucleotide sequence of SEQ ID NO:2,

(c) a foreign DNA carried in *E. coli* JM109 (3D9) (deposit number FERM BP-6929), and

(d) a DNA which hybridizes with a DNA of any one of (a) to (c) under stringent hybridization conditions wherein said DNA encodes a tumor antigen protein which gives rise to tumor antigen peptide(s) that bind(s) to an HLA antigen and are recognized by cytotoxic T lymphocytes.

9. (Currently Amended) A An isolated tumor antigen peptide of 8 to 14 amino acids in length that is a partial peptide derived from the protein of claim 6 a fragment of the amino acid sequence of SEQ ID NO:1, and that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes, or a derivative thereof having which comprises an amino acid residue at position 2 and/or the C-terminus

substituted by another amino acid residue, and which has
functionally equivalent properties.

Claim 10. (Currently Amended) The isolated tumor antigen peptide of claim 9 wherein the HLA antigen is HLA-A24, or a derivative thereof which comprises an amino acid residue at position 2 and/or the C-terminus substituted by another amino acid residue, and which has ~~having~~ the functionally equivalent properties.

Claim 11. (Currently Amended) The isolated tumor antigen peptide of claim 10, which comprises a sequence selected from ~~all~~ ~~or part of~~ an amino acid sequence shown in any one of SEQ ID NOs: 3-18, or a derivative thereof ~~having~~ which comprises a sequence selected from an amino acid sequence shown in any one of SEQ ID NOs: 3-18 wherein the amino acid residue at position 2 and/or the C-terminus is substituted by another amino acid residue and which has the functionally equivalent properties.

Claim 12. (Currently Amended) The isolated tumor antigen peptide of claim 11, which comprises a sequence selected from ~~all~~ ~~or part of~~ an amino acid sequence shown in any one of SEQ ID NOs:

3-5, or a derivative thereof ~~having~~ which comprises a sequence selected from an amino acid sequence shown in any one of SEQ ID NOs: 3-5 wherein the amino acid residue at position 2 and/or the C-terminus is substituted by another amino acid residue and which has the functionally equivalent properties.

Claims 13 - 14. (Canceled).

Claim 15. (Currently Amended) The isolated tumor antigen peptide derivative of claim 11 ~~13~~, which comprises a sequence selected from ~~all or part of~~ an amino acid sequence shown in any one of SEQ ID NOs: 3-18 wherein the amino acid residue at position 2 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the amino acid residue at the C-terminus is substituted by phenylalanine, leucine, isoleucine, tryptophan, or methionine.

Claim 16. (Currently Amended) The isolated tumor antigen peptide derivative of claim 12 ~~14~~, which comprises a sequence selected from ~~all or part of~~ an amino acid sequence shown in any one of SEQ ID NOs: 19-21.

Claim 17. (Currently Amended) A pharmaceutical composition for treating ~~or preventing~~ tumors, which comprises as an active ingredient at least one of substances selected from the isolated tumor antigen peptides and derivatives thereof according to any one of claims 9 to 12, 15, and 16.

Claim 18. (Canceled).

Claim 19. (Currently Amended) A recombinant polypeptide obtainable by expressing a recombinant DNA comprising at least one of DNAs that encode the tumor antigen peptides or derivatives thereof according to any one of claims 9 to 12, 15, and 16.

Claim 20. (Currently Amended) A pharmaceutical composition for treating ~~or preventing~~ tumors, which comprises as an active ingredient the recombinant polypeptide of claim 19.

Claims 21-27. (Canceled).

28. (Currently Amended) A diagnostic agent for tumors, which comprises the tumor antigen peptide or derivative thereof according to any one of claims 9 to 12, 15, and 16, or an isolated the

protein of claim 6 that is encoded by a DNA of any one of the following (a) to (d):

(a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO:1,

(b) a DNA comprising the nucleotide sequence of SEQ ID NO:2,

(c) a foreign DNA carried in *E. coli* JM109 (3D9) (deposit number FERM BP-6929), and

(d) a DNA which hybridizes with a DNA of any one of (a) to (c) under stringent hybridization conditions wherein said DNA encodes a tumor antigen protein which gives rise to tumor antigen peptide(s) that bind(s) to an HLA antigen and are recognized by cytotoxic T lymphocytes.

Claim 29. (Previously Presented) A diagnostic agent for tumors, which comprises the recombinant polypeptide of claim 19.